Scalable electrophysiological investigation of ips cell-derived cardiomyocytes obtained by a lentiviral purification strategy

Journal of Clinical Medicine

Volumn 4, Issue 1, 2015, Pages 102-123

  Friedrichs, Stephanie ^a   Malan, Daniela ^a   Voss, Yvonne ^a,b   Sasse, Philipp ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF SIEGEN   (Germany)

Author keywords

Cardiomyocytes; Induced pluripotent stem cells; Long QT syndrome; Microelectrode array; Planar patch clamp; Purification

Indexed keywords

LENTIVIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL SCREENING; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGICAL PROCEDURES; EMBRYOID BODY; GENE CONSTRUCT; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART RATE; HUMAN; IMMUNOCYTOCHEMISTRY; LONG QT SYNDROME 3; MICROELECTRODE; NONHUMAN; PATCH CLAMP TECHNIQUE; PHENOTYPE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; QT PROLONGATION; REPOLARIZATION; REPORTER GENE; SODIUM CURRENT; VIRAL GENE DELIVERY SYSTEM;

EID: 85067220109     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4010102     Document Type: Article

References (37)

1. Schwartz, P.J.; Priori, S.G.; Spazzolini, C.; Moss, A.J.; Vincent, G.M.; Napolitano, C.; Denjoy, I.; Guicheney, P.; Breithardt, G.; Keating, M.T.; et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103, 89-95.
2. Bennett, P.B.; Yazawa, K.; Makita, N.; George, A.L., Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376, 683-685.
3. Chandra, R.; Starmer, C.F.; Grant, A.O. Multiple effects of KPQ deletion mutation on gating of human cardiac Na+ channels expressed in mammalian cells. Am. J. Physiol. 1998, 274, H1643-H1654.
4. Charpentier, F.; Bourge, A.; Merot, J. Mouse models of SCN5A-related cardiac arrhythmias. Prog. Biophys. Mol. Biol. 2008, 98, 230-237.
5. Malan, D.; Friedrichs, S.; Fleischmann, B.K.; Sasse, P. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ. Res. 2011, 109, 841-847.
6. Itzhaki, I.; Maizels, L.; Huber, I.; Zwi-Dantsis, L.; Caspi, O.; Winterstern, A.; Feldman, O.; Gepstein, A.; Arbel, G.; Hammerman, H.; et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471, 225-229.
7. Matsa, E.; Rajamohan, D.; Dick, E.; Young, L.; Mellor, I.; Staniforth, A.; Denning, C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long qt syndrome type 2 mutation. Eur. Heart J. 2011, 32, 952-962.
8. Lahti, A.L.; Kujala, V.J.; Chapman, H.; Koivisto, A.P.; Pekkanen-Mattila, M.; Kerkela, E.; Hyttinen, J.; Kontula, K.; Swan, H.; Conklin, B.R.; et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2012, 5, 220-230.
9. Davis, R.P.; Casini, S.; van den Berg, C.W.; Hoekstra, M.; Remme, C.A.; Dambrot, C.; Salvatori, D.; Oostwaard, D.W.; Wilde, A.A.; Bezzina, C.R.; et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012, 125, 3079-3091.
10. Egashira, T.; Yuasa, S.; Suzuki, T.; Aizawa, Y.; Yamakawa, H.; Matsuhashi, T.; Ohno, Y.; Tohyama, S.; Okata, S.; Seki, T.; et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 2012, 95, 419-429.
11. Moretti, A.; Bellin, M.; Welling, A.; Jung, C.B.; Lam, J.T.; Bott-Flugel, L.; Dorn, T.; Goedel, A.; Hohnke, C.; Hofmann, F.; et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363, 1397-1409.
12. Stoelzle, S.; Haythornthwaite, A.; Kettenhofen, R.; Kolossov, E.; Bohlen, H.; George, M.; Bruggemann, A.; Fertig, N. Automated patch clamp on mesc-derived cardiomyocytes for cardiotoxicity prediction. J. Biomol. Screen. 2011, 16, 910-916.
13. Mauritz, C.; Schwanke, K.; Reppel, M.; Neef, S.; Katsirntaki, K.; Maier, L.S.; Nguemo, F.; Menke, S.; Haustein, M.; Hescheler, J.; et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008, 118, 507-517.
14. Huber, I.; Itzhaki, I.; Caspi, O.; Arbel, G.; Tzukerman, M.; Gepstein, A.; Habib, M.; Yankelson, L.; Kehat, I.; Gepstein, L. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J. 2007, 21, 2551-2563.
15. Hattori, F.; Chen, H.; Yamashita, H.; Tohyama, S.; Satoh, Y.S.; Yuasa, S.; Li, W.; Yamakawa, H.; Tanaka, T.; Onitsuka, T.; et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat. Methods 2010, 7, 61-66.
16. Kolossov, E.; Bostani, T.; Roell, W.; Breitbach, M.; Pillekamp, F.; Nygren, J.M.; Sasse, P.; Rubenchik, O.; Fries, J.W.; Wenzel, D.; et al. Engraftment of engineered ES cell-derived cardiomyocytes but not bm cells restores contractile function to the infarcted myocardium. J. Exp. Med. 2006, 203, 2315-2327.
17. Kita-Matsuo, H.; Barcova, M.; Prigozhina, N.; Salomonis, N.; Wei, K.; Jacot, J.G.; Nelson, B.; Spiering, S.; Haverslag, R.; Kim, C.; et al. Lentiviral vectors and protocols for creation of stable hesc lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One 2009, 4, e5046.
18. Fang, J.; Qian, J.J.; Yi, S.; Harding, T.C.; Tu, G.H.; VanRoey, M.; Jooss, K. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 2005, 23, 584-590.
19. Pfeifer, A.; Hofmann, A. Lentiviral transgenesis. Methods Mol. Biol. 2009, 530, 391-405.
20. Hosler, B.A.; LaRosa, G.J.; Grippo, J.F.; Gudas, L.J. Expression of REX-1, a gene containing zinc finger motifs, is rapidly reduced by retinoic acid in F9 teratocarcinoma cells. Mol. Cell. Biol. 1989, 9, 5623-5629.
21. Wobus, A.M.; Wallukat, G.; Hescheler, J. Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca2+ channel blockers. Differentiation 1991, 48, 173-182.
22. Friedrichs, S.; Malan, D.; Sasse, P. Modeling long QT syndromes using induced pluripotent stem cells: Current progress and future challenges. Trends Cardiovasc. Med. 2013, 23, 91-98.
23. Nuyens, D.; Stengl, M.; Dugarmaa, S.; Rossenbacker, T.; Compernolle, V.; Rudy, Y.; Smits, J.F.; Flameng, W.; Clancy, C.E.; Moons, L.; et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat. Med. 2001, 7, 1021-1027.
24. Halbach, M.; Egert, U.; Hescheler, J.; Banach, K. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell. Physiol. Biochem. 2003, 13, 271-284.
25. Ma, Y.; Ramezani, A.; Lewis, R.; Hawley, R.G.; Thomson, J.A. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 2003, 21, 111-117.
26. Fontes, A. Cloning technologies. Methods Mol. Biol. 2013, 997, 253-261.
27. Willmann, C.A.; Hemeda, H.; Pieper, L.A.; Lenz, M.; Qin, J.; Joussen, S.; Sontag, S.; Wanek, P.; Denecke, B.; Schuler, H.M.; et al. To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture. PLoS One 2013, 8, e65324.
28. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA Integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004, 2, e234.
29. Vannucci, L.; Lai, M.; Chiuppesi, F.; Ceccherini-Nelli, L.; Pistello, M. Viral vectors: A look back and ahead on gene transfer technology. New Microbiol. 2013, 36, 1-22.
30. Tohyama, S.; Hattori, F.; Sano, M.; Hishiki, T.; Nagahata, Y.; Matsuura, T.; Hashimoto, H.; Suzuki, T.; Yamashita, H.; Satoh, Y.; et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013, 12, 127-137.
31. Malan, D.; Sasse, P. University of Bonn, Bonn, Germany. Unpublished work, 2014.
32. Zandstra, P.W.; Bauwens, C.; Yin, T.; Liu, Q.; Schiller, H.; Zweigerdt, R.; Pasumarthi, K.B.; Field, L.J. Scalable production of embryonic stem cell-derived cardiomyocytes. Tissue Eng. 2003, 9, 767-778.
33. Xu, X.Q.; Zweigerdt, R.; Soo, S.Y.; Ngoh, Z.X.; Tham, S.C.; Wang, S.T.; Graichen, R.; Davidson, B.; Colman, A.; Sun, W.; et al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008, 10, 376-389.
34. Jin, D.; Ni, T.T.; Hou, J.; Rellinger, E.; Zhong, T.P. Promoter analysis of ventricular myosin heavy chain (VMHC) in zebrafish embryos. Dev. Dyn. 2009, 238, 1760-1767.
35. Reiser, P.J.; Portman, M.A.; Ning, X.H.; Schomisch Moravec, C. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1814-H1820.
36. Meyer, T.; Leisgen, C.; Gonser, B.; Gunther, E. QT-screen: High-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev. Technol. 2004, 2, 507-514.
37. Bruegmann, T.; Malan, D.; Hesse, M.; Beiert, T.; Fuegemann, C.J.; Fleischmann, B.K.; Sasse, P. Optogenetic control of heart muscle in vitro and in vivo. Nat. Methods 2010, 7, 897-900.